SEC Form 4 · accession 0000899243-19-000385
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Lambing
Officer — See Remarks
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 9:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2019 | M | 875 | — | A | 95,091 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 1, 2019 | M | 875 | D | — | — | Common Stock | 875 | 2,625 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
Remarks
Senior Vice President, Non-Clinical and Pharmaceutical Development